Ikano Therapeutics, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ikano Therapeutics, Inc.
Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip
The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.
Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
Mérieux and Shire funds back NeuroPhage in $12.4 million round for Alzheimer's
NeuroPhage Pharmaceuticals, a privately held company based in Cambridge, Massachusetts, has been quietly advancing novel approaches to the treatment of neurodegenerative diseases, and now has gained attention by landing $12.4 million in new venture funding. It will use the funds to begin preparations for a Phase I trial of its lead candidate to treat Alzheimer's disease, NPT001, which disaggregates existing beta amyloid plaques.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Nasal
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Intranasal Therapeutics, Inc.